相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al
Lea C. Berkhout et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
Vibeke Strand et al.
BIODRUGS (2020)
The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients
Lea C. Berkhout et al.
RHEUMATOLOGY (2020)
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans
David Ternant et al.
CLINICAL PHARMACOKINETICS (2019)
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study
Nina Wilkinson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay
Lea C. Berkhout et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients
Antonino Cassotta et al.
NATURE MEDICINE (2019)
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
Jocelyn Quistrebert et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis
Sara Pratesi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data
Jean-Hugues Salmon et al.
RHEUMATOLOGY (2018)
Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies
Karin A. van Schie et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Review of immune tolerance induction in hemophilia A
S. J. Schep et al.
BLOOD REVIEWS (2018)
Identification of HLA-DRB1 association to adalimumab immunogenicity
Mohan Liu et al.
PLOS ONE (2018)
Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease
Sophie E. Berends et al.
THERAPEUTIC DRUG MONITORING (2018)
THE EFFECT OF CERTOLIZUMAB DRUG CONCENTRATION AND ANTI-DRUG ANTIBODIES ON TNF NEUTRALISATION
L. C. Berkhout et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
DYNAMICS OF CIRCULATING TNF DURING ADALIMUMAB TREATMENT OF RHEUMATOID ARTHRITIS USING A NOVEL DRUG-TOLERANT TNF ASSAY
L. C. Berkhout et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
Maurizio Benucci et al.
BIOLOGICS-TARGETS & THERAPY (2018)
High frequency of antidrug antibodies and OPEN ACCESS association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
Meghna Jani et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study
E. L. Kneepkens et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2017)
Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site
Karin A. van Schie et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
IL-10-Producing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients
Alessandra Vultaggio et al.
JOURNAL OF IMMUNOLOGY (2017)
Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context
Karien Bloem et al.
THERAPEUTIC DRUG MONITORING (2017)
The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study
Robert J. Moots et al.
PLOS ONE (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies
Karin A. van Schie et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions
A. Vultaggio et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics
Katherine L. Gill et al.
CLINICAL PHARMACOKINETICS (2016)
Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis
Andres J. Yarur et al.
INFLAMMATORY BOWEL DISEASES (2016)
Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen
Guanbo Wang et al.
MOLECULAR CELL (2016)
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
Delphine Bachelet et al.
PLOS ONE (2016)
Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis
Sarah S. Thomas et al.
BIODRUGS (2015)
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis
David Ternant et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis
David Ternant et al.
CLINICAL PHARMACOKINETICS (2015)
IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment
Estelle Freling et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2015)
US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors
L. A. Valentino et al.
HAEMOPHILIA (2015)
Cross-reactive and pre-existing antibodies to therapeutic antibodies-Effects on treatment and immunogenicity
Karin A. van Schie et al.
MABS (2015)
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Angela Schoch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Key findings towards optimising adalimumab treatment: the concentration-effect curve
Mieke F. Pouw et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
Gerd-Rudiger Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Clinical development methodology for infusion-related reactions with monoclonal antibodies
Lucette Doessegger et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2015)
Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
Xavier Roblin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar et al.
GUT (2014)
Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Sorcha O'Meara et al.
INFLAMMATORY BOWEL DISEASES (2014)
Functional Analysis of the Anti-adalimumab Response Using Patient-derived Monoclonal Antibodies
Pauline A. van Schouwenburg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Christoph A. Diebolder et al.
SCIENCE (2014)
Rituximab for treatment of inhibitors in haemophilia A A Phase II Study
Cindy Leissinger et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Niels Vande Casteele et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
Pauline A. van Schouwenburg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
Sandra Garces et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation
Pauline A. van Schouwenburg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study
S. K. Mahil et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Miroslav Dostalek et al.
CLINICAL PHARMACOKINETICS (2013)
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
Anke Vennegoor et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
Pauline A. van Schouwenburg et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions Systematic Review and Meta-analysis
Jose Ramon Maneiro et al.
JAMA INTERNAL MEDICINE (2013)
Factor VIII inhibitors in hemophilia A: rationale and latest evidence
Char Witmer et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
Charlotte L. Krieckaert et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
The principal results of the International Immune Tolerance Study: a randomized dose comparison
Charles R. M. Hay et al.
BLOOD (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Immunogenicity of biological therapeutics: from assay to patient
Charlotte Krieckaert et al.
CURRENT OPINION IN RHEUMATOLOGY (2012)
Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
Casper Steenholdt et al.
INFLAMMATORY BOWEL DISEASES (2012)
IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients
Pauline A. van Schouwenburg et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
Anna Jamnitski et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Venous and Arterial Thromboembolic Events in Adalimumab-Treated Patients With Antiadalimumab Antibodies
L. A. Korswagen et al.
ARTHRITIS AND RHEUMATISM (2011)
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
Dora Pascual-Salcedo et al.
RHEUMATOLOGY (2011)
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
A. Vultaggio et al.
ALLERGY (2010)
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
G. M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Nathanael L. Dirks et al.
CLINICAL PHARMACOKINETICS (2010)
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Ron J. Keizer et al.
CLINICAL PHARMACOKINETICS (2010)
HAHA - nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology
Andreas Nechansky
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2010)
Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
M. K. de Vries et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms
G. M. Bartelds et al.
ARTHRITIS AND RHEUMATISM (2009)
Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans
Geraldine Blanchard-Rohner et al.
BLOOD (2009)
Dealing with immunogenicity of biologicals: assessment and clinical relevance
Gerrit J. Wolbink et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
Activation of natural regulatory T cells by IgG Fc-derived peptide Tregitopes
Anne S. De Groot et al.
BLOOD (2008)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
Jinhai Wang et al.
NATURE BIOTECHNOLOGY (2008)
The incidence and significance of anti-natalizumab antibodies -: Results from AFFIRM and SENTINEL
P. A. Calabresi et al.
NEUROLOGY (2007)
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange
Marijn van der Neut Kolfschoten et al.
SCIENCE (2007)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis
C. J. van der Laken et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Leonard G. Presta
ADVANCED DRUG DELIVERY REVIEWS (2006)
High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors
C Hausl et al.
BLOOD (2005)
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys
JR Rojas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Immunogenicity of engineered antibodies
WYK Hwang et al.
METHODS (2005)
Overview of monoclonal antibodies in cancer therapy: present and promise
M Stern et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
The epidemiology of inhibitors in haemophilia A: a systematic review
J Wight et al.
HAEMOPHILIA (2003)
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
N Casadevall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies
RJ Ober et al.
INTERNATIONAL IMMUNOLOGY (2001)
Infliximab for Crohn's disease in clinical practice at the mayo clinic: The first 100 patients
E Ricart et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2001)
Antibody humanization: a case of the 'Emperor's new clothes'?
M Clark
IMMUNOLOGY TODAY (2000)
分享论文
